Fountain Therapeutics Appoints William L. Greene, M.D. Chief Executive Officer
SOUTH SAN FRANCISCO, Calif., April 26, 2021 — Fountain Therapeutics, a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced the appointment of William L. Greene, M.D. as the company’s chief executive officer, effective April 26, 2021. Dr. Greene was appointed to the Fountain Board of Directors …
Fountain Therapeutics Appoints William L. Greene, M.D. Chief Executive Officer Read More »
Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease
The biopharma industry has high ambitions to improve therapies for patients across many disease categories, drawing on a wealth of technological advances that have been emerging and maturing in recent years.
Biopharma Executive Perspectives on 2021
When our backs were against the wall, the biotech/biopharma community came together to create not one, but two vaccines currently approved for emergency use in the U.S. This has earned the industry a lot of respect.
A year in Longevity: science perspectives
Over the past year, we’ve had the pleasure of speaking to some of the Longevity sector’s most influential people. From expert views on biomarkers and interventions, the definition of biological age, the secret to healthy aging, or AI and COVID-19, we’ve put together some of our favourites.
View From The Inside: What’s Shaping Biopharma In 2021 And Beyond?
About a year ago, Life Science Leader Chief Editor Rob Wright posed questions to several biopharma leaders for a column in the 2019 iteration of this annual Outlook issue.
HQ Move Fuels Fountain’s AI Drug Discovery Machine
Fountain Therapeutics’ unique AI discovery platform prompted an invitation from Eli Lilly & Company to move Fountain headquarters to Lilly Gateway Labs. Company CEO Dr. John Dimos is making the most of it.